Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American... Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/01/2020 REVIEW ARTICLE Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture J. Fernando Arevalo, MD, FACS, and T.Y. Alvin Liu, MD; for the Pan-American Collaborative Retina Study Group (PACORES) The purpose of this review article is to summarize results Abstract: The advent of intravitreal anti‒vascular endothelial growth of clinical studies carried out by the Pan‑American Collabora ‑ factor (anti‑VEGF) medications has revolutionized the treatment of tive Retina Study Group (PACORES), with a specific focus on diabetic eye diseases. Herein, we report the outcomes of clinical stud‑ the treatment of DME and PDR with intravitreal bevacizumab. ies carried out by the Pan‑American Collaborative Retina Study Group The PACORES is a collaborative research consortium, currently (PACORES), with a specific focus on the efficacy of intravitreal bevaci‑ involving 19 centers in 13 countries across Latin America and zumab in the management of diabetic macular edema and proliferative Spain. diabetic retinopathy. We will also discuss the use of intravitreal bevaci‑ zumab as a preoperative, adjuvant therapy before vitrectomy for prolif‑ erative diabetic retinopathy. IntravItreal BevacIzumaB for the treatment of Dme Key Words: intravitreal injections, bevacizumab, proliferative diabetic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Asia-Pacific Journal of Ophthalmology Wolters Kluwer Health

Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

Loading next page...
 
/lp/wolters-kluwer-health/intravitreal-bevacizumab-in-diabetic-retinopathy-recommendations-from-0dJKNFFLTY
Publisher
Wolters Kluwer Health
ISSN
2162-0989
eISSN
2475-5028
DOI
10.22608/APO.2017466
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/01/2020 REVIEW ARTICLE Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture J. Fernando Arevalo, MD, FACS, and T.Y. Alvin Liu, MD; for the Pan-American Collaborative Retina Study Group (PACORES) The purpose of this review article is to summarize results Abstract: The advent of intravitreal anti‒vascular endothelial growth of clinical studies carried out by the Pan‑American Collabora ‑ factor (anti‑VEGF) medications has revolutionized the treatment of tive Retina Study Group (PACORES), with a specific focus on diabetic eye diseases. Herein, we report the outcomes of clinical stud‑ the treatment of DME and PDR with intravitreal bevacizumab. ies carried out by the Pan‑American Collaborative Retina Study Group The PACORES is a collaborative research consortium, currently (PACORES), with a specific focus on the efficacy of intravitreal bevaci‑ involving 19 centers in 13 countries across Latin America and zumab in the management of diabetic macular edema and proliferative Spain. diabetic retinopathy. We will also discuss the use of intravitreal bevaci‑ zumab as a preoperative, adjuvant therapy before vitrectomy for prolif‑ erative diabetic retinopathy. IntravItreal BevacIzumaB for the treatment of Dme Key Words: intravitreal injections, bevacizumab, proliferative diabetic

Journal

The Asia-Pacific Journal of OphthalmologyWolters Kluwer Health

Published: Jan 1, 2018

There are no references for this article.